Want to see UPC full AI Analyst Report?
Universe Pharmaceuticals (UPC) AI Stock Analysis
Universe Pharmaceuticals
(NASDAQ:UPC)
The overall score of 38 reflects critical weaknesses across the board. The primary negative drivers are significant operational deterioration, marked by steep revenue declines and cash burn, coupled with a severe technical downtrend. While the balance sheet carries low debt, the company's inability to generate positive cash flow and deeply unprofitable valuation metrics keep the stock's profile heavily pressured.
Universe Pharmaceuticals (UPC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $941.32K
- Dividend Yield
- ―
- Average Volume (3M)
- 603.10K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 3.27
- Revenue Growth
- -8.04%
- EPS Growth
- -100.01%
- Country
- US
- Employees
- 216
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Universe Pharmaceuticals Business Overview & Revenue Model
Company Description
Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These rem...
Universe Pharmaceuticals Financial Statement Overview
Summary
The company faces severe operational deterioration with steep revenue declines, sustained net losses, and negative cash flows, though its low debt levels provide some balance sheet stability.
Income Statement
15Very NegativeBalance Sheet
68PositiveCash Flow
20Very Negative| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.74M | 17.86M | 23.02M | 32.31M | 40.14M | 47.98M |
| Gross Profit | 6.36M | 6.30M | 6.07M | 10.32M | 21.89M | 25.33M |
| EBITDA | -1.31M | -2.92M | -7.36M | -3.18M | -6.40M | 14.20M |
| Net Income | -1.94M | -3.67M | -8.73M | -6.16M | -8.74M | 11.32M |
Balance Sheet | ||||||
| Total Assets | 71.47M | 69.30M | 67.95M | 53.29M | 59.54M | 70.14M |
| Cash, Cash Equivalents and Short-Term Investments | 29.05M | 33.59M | 29.50M | 18.50M | 18.86M | 21.80M |
| Total Debt | 9.55M | 9.26M | 7.99M | 5.48M | 3.94M | 4.33M |
| Total Liabilities | 15.82M | 13.17M | 22.45M | 13.75M | 13.10M | 11.21M |
| Stockholders Equity | 55.65M | 56.13M | 45.50M | 39.53M | 46.44M | 58.93M |
Cash Flow | ||||||
| Free Cash Flow | -12.39M | -5.40M | -9.87M | 1.08M | -1.41M | -15.59M |
| Operating Cash Flow | -11.91M | -5.05M | -9.51M | 1.12M | -1.31M | -2.06M |
| Investing Cash Flow | -2.02M | -341.81K | -361.29K | -44.17K | -3.91M | -27.06M |
| Financing Cash Flow | -6.82M | 9.73M | 33.95M | -1.39M | 3.32M | 26.58M |
Universe Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPC, the sentiment is Negative. The current price of 1.49 is below the 20-day moving average (MA) of 3.61, below the 50-day MA of 4.22, and below the 200-day MA of 3.82, indicating a bearish trend. The MACD of -0.66 indicates Positive momentum. The RSI at 22.24 is Positive, neither overbought nor oversold. The STOCH value of 1.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPC.
Universe Pharmaceuticals Risk Analysis
Universe Pharmaceuticals disclosed 69 risk factors in its most recent earnings report. Universe Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksUniverse Pharmaceuticals Peers Comparison
Overall Rating
CPHI56Neutral
RDHL41Neutral
PRFX38Underperform- UPC38Underperform
SHPH32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CPHI | 56Neutral | $26.88M | -0.62 | -17.14% | ― | -10.97% | 71.83% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| RDHL | 41Neutral | $3.45M | -2.85 | 206.75% | ― | ― | ― |
| PRFX | 38Underperform | $2.22M | -0.07 | -72.87% | ― | ― | ― |
| UPC | 38Underperform | $7.49M | -0.43 | -3.48% | ― | -8.04% | -100.01% |
| SHPH | 32Underperform | $24.54M | -0.17 | -156.78% | ― | ― | 94.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UPC | Universe Pharmaceuticals Incorporation | 1.49 | -3.11 | -67.61% | |
| CPHI | China Pharma | 0.62 | -1.01 | -61.72% | |
| RDHL | RedHill Biopharma Ltd | 0.39 | -0.88 | -69.53% | |
| SXTC | China Sxt Pharmaceuticals | 3.25 | -1691997.05 | -100.00% | |
| PRFX | Painreform Ltd. | 0.73 | -5.07 | -87.41% | |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. | 5.15 | -25.85 | -83.39% |
Universe Pharmaceuticals Corporate Events
Universe Pharmaceuticals Shareholders Approve Board Slate and Conditional Reverse Split at 2026 AGM
Universe Pharmaceuticals Inc. held its 2026 Annual General Meeting of Shareholders on September 30, 2026 in Ji’an, Jiangxi, where investors representing about 88.48% of voting rights were present, ensuring a valid quorum. Shareholders re-electe...
Universe Pharmaceuticals Sets September 30, 2026 AGM With Contingent Reverse Stock Split Proposal
Universe Pharmaceuticals has called its 2026 Annual General Meeting of Shareholders for September 30, 2026, in Ji’an, Jiangxi, China, setting August 31, 2026, as the record date for investors eligible to vote. Shareholders will consider the re&...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026